Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced installation of its Genesis Robotic Magnetic Navigation system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment of cardiac arrhythmias.
ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its Genesis Robotic Magnetic Navigation (RMN) system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment of cardiac arrhythmias.
Electrophysiologists at Princess Grace Hospital have been among the pioneers of robotic cardiac ablation in Europe, becoming early adopters of Stereotaxis technology in 2006. Since then, more than 1,000 patients in Monaco have benefited from the precision and safety of Robotic Magnetic Navigation. Dr. Gabriel Latcu, head of electrophysiology and deputy head of cardiology services at Princess Grace Hospital, has successfully treated the first patients with the new Genesis Robot, the first procedures performed with the technology in Southern Europe.
“Robotic Magnetic Navigation has been a central technology in enabling us to successfully treat and research complex arrhythmias,” says Dr. Latcu. “With the latest advances in RMN technology, we expect the Genesis system to further enhance our capability to pioneer better care for patients suffering from heart rhythm disorders.”
“We are proud leaders of education and innovative treatments of arrhythmias,” says Prof. Atul Pathak, chief of cardiology at Princess Grace Hospital. “Stereotaxis has been a strong, long-term partner in our efforts to provide the highest quality treatments, to expand medical knowledge, and to train the next generation of electrophysiologists.”
Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, certain arrhythmias can significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“We look forward to continuing to support Princess Grace Hospital’s mission to advance the future of electrophysiology and appreciate their partnership in establishing the Genesis robotic system as a central technology for the future of the field,” said David Fischel, Chairman and CEO of Stereotaxis.
About Stereotaxis
Stereotaxis (NYSE: STXS) is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ Robotic Magnetic Navigation technology is used in the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com or follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
